JAMA Oncology Journal

Overview
Identity
View All

publication venue for

Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis. 8:1809-1809. 2022
Prophylactic Antibiotic Regimens in Tumor Resection Surgery Involving a Prosthesis—Reply. 8:1222-1222. 2022
Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation Therapy. 8:853-853. 2022
Biased Evaluation in Cancer Drug Trials—How Use of Progression-Free Survival as the Primary End Point Can Mislead. 8:679-679. 2022
Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation. 8:579-579. 2022
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019. 8:420-420. 2022
Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors. 8:345-345. 2022
Metformin—A Thought-provoking Addition to Anticancer Therapies—Reply. 8:303-303. 2022
Performance of the McGill Interactive Pediatric OncoGenetic Guidelines for Identifying Cancer Predisposition Syndromes. 7:1806-1806. 2021
Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators. 7:e213428-e213428. 2021
Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non–Small Cell Lung Cancer. 7:1324-1324. 2021
Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer. 7:1333-1333. 2021
Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy. 7:1196-1196. 2021
Central Nervous System–Specific Outcomes of Phase 3 Randomized Clinical Trials in Patients With Advanced Breast Cancer, Lung Cancer, and Melanoma. 7:1062-1062. 2021
Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. 7:773-773. 2021
Comparison of Multiparametric Magnetic Resonance Imaging–Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer. 7:534-534. 2021
Efficacy and Safety of nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer. 6:1751-1751. 2020
Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplant and Lymphoma. 6:989-989. 2020
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer. 6:831-831. 2020
Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. 6:505-505. 2020
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. 5:1749-1749. 2019
Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With “Good Prognosis” Rectal Cancer Eligible for Primary Surgery. 5:961-961. 2019
Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy. 5:664-664. 2019
Therapeutic Options for Neuroendocrine Tumors. 5:480-480. 2019
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2016. 4:1553-1553. 2018
Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. 4:1059-1059. 2018
Effect of Radiotherapy on Painful Bone Metastases. 3:953-953. 2017
Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma. 3:366-366. 2017
Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma. 3:220-220. 2017
Clarifying Assumptions and Outcomes in Cost-Effectiveness Analyses—Reply. 2:278-278. 2016
Cost-effectiveness of Lung Cancer Screening in Canada. 1:807-807. 2015
The Global Burden of Cancer 2013. 1:505-505. 2015
Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. 1:359-359. 2015

has subject area

1112 Oncology and Carcinogenesis (FoR)
1117 Public Health and Health Services (FoR)